Therefore, various approaches to prevent GVHD are being investigated, including in vitro T-cell depletion of bone marrow or peripheral blood stem cells (PBSCs) or, more recently, in vivo T-cell depletion approaches using either granulocyte colony-stimulating factor (G-CSF)-mobilized bone marrow in combination with PBSCs and anti-thymocyte globulin or the administration of high-dose cyclophosphamide after transplantation of haploidentical bone marrow-derived progenitor cells [6]. The gene discussed is CSF3; the disease is graft versus host disease.